Throughout the last three months, 4 analysts have evaluated ADMA Biologics (NASDAQ:ADMA), offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $20.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 20.63% from the previous average price target of $15.75.

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of ADMA Biologics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Capture valuable insights into ADMA Biologics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on ADMA Biologics analyst ratings.

Unveiling the Story Behind ADMA Biologics

Financial Milestones: ADMA Biologics's Journey

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: ADMA Biologics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 78.29%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: ADMA Biologics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 29.91% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): ADMA Biologics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.75% ROE, the company effectively utilizes shareholder equity capital.

Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 8.82%, the company showcases effective utilization of assets.

Debt Management: ADMA Biologics's debt-to-equity ratio surpasses industry norms, standing at 0.75. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Analyst Ratings: Simplified

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.